Climb Bio (CLYM) Competitors $1.26 -0.11 (-8.03%) As of 06/11/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CLYM vs. CYRX, IVA, SLDB, PHAT, ARCT, TERN, NGNE, TKNO, AURA, and HRTXShould you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include Cryoport (CYRX), Inventiva (IVA), Solid Biosciences (SLDB), Phathom Pharmaceuticals (PHAT), Arcturus Therapeutics (ARCT), Terns Pharmaceuticals (TERN), Neurogene (NGNE), Alpha Teknova (TKNO), Aura Biosciences (AURA), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry. Climb Bio vs. Its Competitors Cryoport Inventiva Solid Biosciences Phathom Pharmaceuticals Arcturus Therapeutics Terns Pharmaceuticals Neurogene Alpha Teknova Aura Biosciences Heron Therapeutics Climb Bio (NASDAQ:CLYM) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking. Which has more volatility & risk, CLYM or CYRX? Climb Bio has a beta of -0.16, indicating that its stock price is 116% less volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Is CLYM or CYRX more profitable? Climb Bio has a net margin of 0.00% compared to Cryoport's net margin of -70.08%. Cryoport's return on equity of -13.35% beat Climb Bio's return on equity.Company Net Margins Return on Equity Return on Assets Climb BioN/A -42.21% -41.39% Cryoport -70.08%-13.35%-6.43% Does the media refer more to CLYM or CYRX? In the previous week, Cryoport had 3 more articles in the media than Climb Bio. MarketBeat recorded 8 mentions for Cryoport and 5 mentions for Climb Bio. Cryoport's average media sentiment score of 0.99 beat Climb Bio's score of 0.57 indicating that Cryoport is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cryoport 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in CLYM or CYRX? Cryoport received 247 more outperform votes than Climb Bio when rated by MarketBeat users. However, 83.33% of users gave Climb Bio an outperform vote while only 65.80% of users gave Cryoport an outperform vote. CompanyUnderperformOutperformClimb BioOutperform Votes583.33% Underperform Votes116.67%CryoportOutperform Votes25265.80% Underperform Votes13134.20% Which has higher valuation & earnings, CLYM or CYRX? Climb Bio has higher earnings, but lower revenue than Cryoport. Cryoport is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClimb BioN/AN/A-$35.12M-$2.38-0.53Cryoport$232.13M1.49-$99.59M-$2.34-2.95 Do analysts prefer CLYM or CYRX? Climb Bio presently has a consensus price target of $9.00, indicating a potential upside of 614.29%. Cryoport has a consensus price target of $11.00, indicating a potential upside of 59.19%. Given Climb Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Climb Bio is more favorable than Cryoport.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Climb Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Cryoport 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Do insiders & institutionals believe in CLYM or CYRX? 69.8% of Climb Bio shares are held by institutional investors. Comparatively, 92.9% of Cryoport shares are held by institutional investors. 0.8% of Climb Bio shares are held by company insiders. Comparatively, 10.0% of Cryoport shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryCryoport beats Climb Bio on 11 of the 18 factors compared between the two stocks. Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLYM vs. The Competition Export to ExcelMetricClimb BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.15M$6.85B$5.57B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.598.7827.1420.06Price / SalesN/A255.49419.32157.08Price / CashN/A65.8538.2534.64Price / Book0.326.557.064.70Net Income-$35.12M$143.93M$3.23B$247.88M7 Day Performance1.61%3.84%2.83%2.63%1 Month Performance1.61%11.20%9.02%6.36%1 Year PerformanceN/A4.18%31.36%14.05% Climb Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLYMClimb Bio3.1206 of 5 stars$1.26-8.0%$9.00+614.3%N/A$85.15MN/A-0.599CYRXCryoport3.5329 of 5 stars$6.66+7.8%$11.00+65.2%-34.9%$333.91M$232.13M-1.971,020Insider TradeIVAInventiva2.1469 of 5 stars$3.46+2.2%$10.40+201.0%+8.3%$330.51M$9.20M0.00100News CoverageGap DownSLDBSolid Biosciences3.7755 of 5 stars$4.25+10.7%$14.90+250.6%-38.6%$329.44M$8.09M-1.40100Analyst RevisionHigh Trading VolumePHATPhathom Pharmaceuticals4.0871 of 5 stars$4.69-0.2%$17.60+275.3%-18.0%$327.43M$81.86M-0.82110Analyst ForecastOptions VolumeARCTArcturus Therapeutics3.2664 of 5 stars$11.91-2.9%$53.50+349.2%-61.6%$323.01M$131.27M-5.36180News CoveragePositive NewsAnalyst RevisionTERNTerns Pharmaceuticals4.1754 of 5 stars$3.54+0.9%$15.63+341.4%-44.1%$309.17MN/A-3.0040Positive NewsNGNENeurogene3.6578 of 5 stars$22.92+5.8%$44.60+94.6%-43.7%$309.06M$925K-5.2790Positive NewsTKNOAlpha Teknova2.8142 of 5 stars$5.77-0.3%$8.50+47.3%+233.5%$308.36M$38.25M-7.80240Positive NewsAURAAura Biosciences2.5596 of 5 stars$6.10-0.7%$22.00+260.7%-7.1%$306.64MN/A-3.5350Positive NewsHRTXHeron Therapeutics3.935 of 5 stars$2.00-2.0%$5.50+175.0%-43.4%$305.13M$148.52M-11.11300News CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Cryoport Competitors Inventiva Competitors Solid Biosciences Competitors Phathom Pharmaceuticals Competitors Arcturus Therapeutics Competitors Terns Pharmaceuticals Competitors Neurogene Competitors Alpha Teknova Competitors Aura Biosciences Competitors Heron Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLYM) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
